Elektrofi utilizes its hyper concentration microparticle technology, Hypercon™, to enable subcutaneous self-administration of biologic therapies, specifically targeting monoclonal antibodies and therapeutic proteins. This approach eliminates the need for intravenous delivery, allowing patients to receive their medications conveniently at home, thereby enhancing treatment adherence and patient autonomy.
Funding
$158.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RPFounders
Product
Problem
Many biologic therapies, such as monoclonal antibodies and therapeutic proteins, require intravenous (IV) administration, which can be inconvenient for patients and necessitate visits to healthcare facilities. This dependence on IV delivery can reduce patient adherence and limit access to treatment, particularly for those with mobility issues or who live far from medical centers.
Solution
Elektrofi is developing a technology called Hypercon™ that enables subcutaneous (SC) delivery of high-concentration biologics, transforming how patients receive these medications. The Hypercon™ platform allows formulations of monoclonal antibodies and therapeutic proteins to be administered via a simple SC injection, potentially eliminating the need for IV infusions. This approach offers the convenience of at-home self-administration, improving patient autonomy and adherence to prescribed treatment regimens. By converting IV therapies to SC injections, Elektrofi aims to improve the patient experience and expand access to critical biologic medicines.
Target Audience
Elektrofi's primary customers are pharmaceutical companies developing biologic therapies, as well as patients who require frequent or long-term administration of these medications.
Features
- Hypercon™ technology enables highly concentrated formulations of biologics.
- Allows for subcutaneous injection of drugs traditionally administered intravenously.
- Designed for self-administration, reducing the need for clinic visits.
- Aims to improve patient adherence and convenience.
- Focuses on monoclonal antibodies and therapeutic proteins.